DexCom earnings beat by $0.03, revenue topped estimates
Gregg Williams, a director and significant shareholder of Vivani Medical (TASE:BLWV), Inc. (NASDAQ:VANI), recently acquired additional shares of the company. According to a recent SEC filing, Williams purchased a total of 20,840 shares of Vivani Medical common stock in two separate transactions. The purchases, made on April 9 and April 11, were executed at an average price range between $1.01 and $1.02 per share, amounting to a total investment of $21,233. The stock, which has shown significant volatility according to InvestingPro data, is currently trading at $1.02, down about 51% over the past year.
Following these transactions, Williams now holds a total of 13,825,230 shares, which includes shares owned indirectly through various trusts and investment entities. His indirect holdings comprise shares owned by the Gregg G. Williams 2006 Trust, Williams International Co. LLC, Sam Williams Family Investments LLC, and the Sam B. Williams 1995 Generation-Skipping Trust. Williams maintains voting and dispositive power over all these shares. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 3.41, though analysts don’t expect profitability this year. Get access to 7 more exclusive InvestingPro Tips for deeper insights into VANI’s financial health.
In other recent news, Vivani Medical, Inc. reported a net loss of $23.5 million for 2024, aligning closely with analyst expectations from H.C. Wainwright. The firm maintained its Buy rating and a $4.00 price target on Vivani Medical, reflecting confidence in the company’s progress. Vivani Medical also secured approximately $8.25 million through a private placement to advance its drug implant development, particularly for NPM-139 and NPM-115, which are designed for chronic weight management. The company announced successful full enrollment in its Phase 1 LIBERATE-1 trial for the exenatide implant NPM-115, with top-line results anticipated by mid-2025.
Additionally, Vivani Medical shared promising preclinical results for its semaglutide implant, NPM-139, showing significant weight loss in a study involving healthy rats. The implant demonstrated consistent exposure to semaglutide, with the potential for once or twice-yearly dosing. The company’s NanoPortal technology is pivotal in these developments, aiming to improve medication adherence and patient outcomes. Vivani Medical’s management remains optimistic about the potential of its GLP-1 implants to transform treatment standards for metabolic diseases. These recent developments highlight Vivani Medical’s ongoing efforts to innovate in the field of chronic weight management and type 2 diabetes treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.